Benzinga | Sep 21, 2020 09:40AM EDT

Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $170

Piper Sandler maintains Mirati Therapeutics (NASDAQ:MRTX) with a Overweight and raises the price target from $145 to $170.